Advertisement

Topics

Cambridge Epigenetix Company Profile

23:02 EDT 18th June 2019 | BioPortfolio

Cambridge Epigenetix’s mission is to improve health through the routine measurement of the epigenome. Cambridge Epigenetix utilizes innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com


News Articles [287 Associated News Articles listed on BioPortfolio]

Cambridge Epigenetix announces programme for routine screening and detection of colorectal ...

Company announces the appointment of new Chief Executive, Dr Suman Shirodkar, to lead the advancement of its scientific programmes. Read more...

Cambridge Epigenetix announces programme for routine screening and detection of colorectal cancer and other common tumours

Company granted broad and exclusive patent rights for the use of an epigenetic biomarker as a diagnostic tool for cancer. 5-hydroxymethylcytosine (5hmC) epigenetic sequen...

Cambridge BioTech Week 2019 aims to shine spotlight on innovations in the Cambridge cluster

The city of Cambridge, a global hub for research and healthcare innovation, is to host Cambridge BioTech Week from 24-28 June 2019.

Cambridge BioTech Week to showcase innovation in the Cambridge cluster in June 2019

The city of Cambridge, a global hub for research and healthcare innovation, is to host Cambridge BioTech Week from 24-28 June 2019. The week will feature a series of events dedicated to celebrating, s...

Cambridge Fund Raises €175M to Supercharge Local Life Sciences Ecosystem

The UK venture capital fund Cambridge Innovation Capital, backed by the University of Cambridge, has raised €175M (£150M) to spend on life science and technology companies in the Cambridge area. Th...

Backing Cambridge's AI boom

How Cambridge Innovation Capital is deploying its £150 million fund to back U.K. start-ups.

Sanofi Moving 2,700 Staffers From the Boston Suburbs to Cambridge Crossing

Paris-based Sanofi signed the lease on two buildings yet to be built in East Cambridge, Massachusetts. Sanofi is the state’s largest life science employer and plans to shift 2,700 staffers into the ...

OGT to Open New Cytocell Facility in Cambridge, UK

Sysmex demonstrates confidence and investment in OGT and the United Kingdom. Oxford Gene Technology, The Molecular Genetics Company, has announced that it is expanding its Cytocell®operations with...

Drugs and Medications [7 Associated Drugs and Medications listed on BioPortfolio]

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Diclofenac sodium [cambridge therapeutics technologies, llc]

Diclofenac Sodium Delayed-release Tablets, USP

Amoxicillin and clavulanate potassium [cambridge therapeutics technologies, llc]

These highlights do not include all the information needed to use AMOXICILLIN AND CLAVULANATE POTASSIUM, USP safely and effectively. See full prescribing information for AMOXICILLIN AND CLAVULANATE PO...

Metformin hydrochloride [cambridge therapeutics technologies, llc]

Metformin Hydrochloride Tablets USP

Metronidazole500 mg [cambridge therapeutics technologies, llc]

Metronidazole Tablets, USPRx Only 

Clinical Trials [38 Associated Clinical Trials listed on BioPortfolio]

Weight Loss for Obese Individuals With Gout

This study evaluates effect of weight loss in a group of obese patients with gouty arthritis. The study is a randomised group trial where half the patients receive intensive weight loss in...

PAN-study: Pan-Cancer Early Detection Study (PAN)

The PAN Cancer Early Detection study is a prospective cross-sectional observational case-control study evaluating whether Breath Biopsy (developed by Owlstone Medical Ltd.; the Sponsor of...

Color Vision as a Measure for Inherited Retinal Diseases

Background: - The purpose of this study is to find out whether color vision measured with the Cambridge Color Test is a good way to examine the severity of inherited retinal diseases (IRD...

Mayo AVC Registry and BioBank

Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death i...

Cambridge Anti-Myopia Trial: Accommodation Training and Aberration Control in Myopia Development

We have identified focussing problems related to myopia getting worse. Our trial uses optical and orthoptic interventions that correct the focussing problems to see if this retards myopia ...

Companies [411 Associated Companies listed on BioPortfolio]

Cambridge Cognition Ltd

Cambridge Cognition Ltd specialises in computerised cognitive testing. Based in Cambridge, England, the company supplies products and services based on CANTAB®, the Cambridge Neuropsychological Test ...

Cambridge Epigenetix

Cambridge Epigenetix’s mission is to improve health through the routine measurement of the epigenome. Cambridge Epigenetix utilizes innovative technologies, often based on fu...

Cambridge Biomedical, Inc.

Cambridge Biomedical is a contract research organization (CRO) and diagnostic laboratory providing bioanalytical support to the pharmaceutical, biotechnology, and medical d...

Funxional Therapeutics Limited

Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced t...

Cambridge University Press

Cambridge University Press was founded by a royal charter granted to the University of Cambridge by King Henry VIII in 1534. It is the oldest printer and publisher in the world, having been operating ...

More Information about "Cambridge Epigenetix" on BioPortfolio

We have published hundreds of Cambridge Epigenetix news stories on BioPortfolio along with dozens of Cambridge Epigenetix Clinical Trials and PubMed Articles about Cambridge Epigenetix for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Epigenetix Companies in our database. You can also find out about relevant Cambridge Epigenetix Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Epigenetics
The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...


Corporate Database Quicklinks



Searches Linking to this Company Record